The University of Texas M.D. Anderson Cancer Center is a freestanding, categorical academic institution established within the University of Texas System by the Texas legislature in Houston in 1941. In 1954, the M.D. Anderson was moved to its current location in the Texas Medical Center in close proximity to other leading biomedical research institutions. The mission of the M.D. Anderson is to eliminate cancer and allied diseases as significant health problems throughout Texas, the nation and the world by developing and maintaining integrated quality programs in patient care, research, education and prevention. M.D. Anderson is dedicated wholly to the study of cancer involving a continuum of research in the basic sciences, clinical investigations and population- based research, with an emphasis on multi-disciplinary translational activities. Faculty investigators are engaged in the transfer of new technology and basic laboratory advances to the clinic, in providing cutting-edge clinical programs including both inpatient and outpatient care, and in community outreach aimed primarily at screening and early detection. The research activities of M.D. Anderson are organized into 28 research programs which include 7 basic science research programs, 18 clinical research programs consisting of 11 disciplinary disease-site programs and 7 thematic programs, and 3 population-based research programs as described in this renewal. The research is supported by the 13 CCSG Core Facilities described in the application for which funding is requested These include 11 currently funded facilities: Automated Cytometry and Cell sorter/Confocal Microscopy and Image Analysis, High Resolution Electron Microscope. Tissue Procurement and Banking, Centralized Histopathology, Research Animal Support, Veterinary Research Support, Cancer Information Systems, Biostatistical Resource Group, Macromolecular Analysis, Synthetic Antigen Laboratory, and Clinical Trials Support, as well as two new facilities, the Pharmacology and Analytical Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Development, Planning and Evaluation, and for partial salary support for Senior Leadership and Program Directors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6504716
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-07-01
Project End
2003-06-30
Budget Start
2001-09-28
Budget End
2002-06-30
Support Year
26
Fiscal Year
2001
Total Cost
$199,271
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications